<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03316261</url>
  </required_header>
  <id_info>
    <org_study_id>GPPAD-02</org_study_id>
    <nct_id>NCT03316261</nct_id>
  </id_info>
  <brief_title>Freder1k-Study - Testing Infants for Type 1 Diabetes Risk</brief_title>
  <official_title>Freder1k-Study - Identification of Infants With Increased Type 1 Diabetes Risk for Enrollment Into Primary Prevention Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helmholtz Zentrum München</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helmholtz Zentrum München</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Freder1k-Study will identify infants who have a high genetic risk of type 1 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 1 diabetes is a common chronic disease in childhood and is increasing in incidence. Type&#xD;
      1 diabetes is diagnosed by hyperglycemia often in combination with symptoms of weight loss,&#xD;
      thirst, fatigue and frequent urination, sometimes with ketoacidosis. The clinical onset is&#xD;
      preceded by an asymptomatic phase identified by serum multiple beta-cell autoantibodies.&#xD;
      Neonates and infants who are at increased risk to develop multiple beta-cell autoantibodies&#xD;
      and type 1 diabetes can now be identified using genetic markers. This provides opportunity&#xD;
      for introducing early therapies to prevent beta-cell autoimmunity and type 1 diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2017</start_date>
  <completion_date type="Anticipated">February 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 29, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>greater than 10% risk for multiple beta-cell autoantibodies/type 1 diabetes</measure>
    <time_frame>one-time testing before age 7 days</time_frame>
    <description>increased risk will be identified by risk scores derived from SNPs</description>
  </primary_outcome>
  <enrollment type="Anticipated">318000</enrollment>
  <condition>Identification of Infants at Risk for Type 1 Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The Freder1k-Study will identify infants who have a high genetic risk of type 1 diabetes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: up to age 7 days&#xD;
&#xD;
          -  provided written informed consent by custodial parent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anette-Gabriele Ziegler</last_name>
    <role>Study Chair</role>
    <affiliation>Helmholtz Zentrum München, IDF-1</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anette-Gabriele Ziegler</last_name>
    <phone>0800-000 0018</phone>
    <email>contact@gppad.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christiane Winkler</last_name>
    <phone>0049-89-31873745</phone>
    <email>contact@gppad.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut für Diabetesforschung, Helmholtz Zentrum München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette-G. Ziegler, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.gppad.org</url>
    <description>GPPAD</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helmholtz Zentrum München</investigator_affiliation>
    <investigator_full_name>Anette-Gabriele Ziegler</investigator_full_name>
    <investigator_title>Director - Institute of Diabetes Research</investigator_title>
  </responsible_party>
  <keyword>infants</keyword>
  <keyword>type 1 diabetes</keyword>
  <keyword>Freder1k</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

